Table 3 Effects of subgroups on survival rates in nasopharyngeal carcinoma underwent CV-IMRT versus RV-IMRT
Variate | 3-year OS | 3-year PFS | 3-year DMFS | 3-year LRRFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CV-IMRT | RV-IMRT | P | CV-IMRT | RV-IMRT | P | CV-IMRT | RV-IMRT | P | CV-IMRT | RV-IMRT | P | ||
Sex | Female | 91.7% | 95.5% | 1 | 91.7% | 95.5% | 1 | 100.0% | 95.5% | 0.478 | 91.7% | 100.0% | 0.49 |
Male | 87.9% | 91.2% | 0.583 | 81.8% | 82.4% | 1 | 89.4% | 88.2% | 1 | 90.9% | 91.2% | 1 | |
Age | < 45 | 95.0% | 90.0% | 0.675 | 95.0% | 80.0% | 0.087 | 97.5% | 85.0% | 0.108 | 97.5% | 90.0% | 0.359 |
≥45 | 84.0% | 94.0% | 0.2 | 76.0% | 90.0% | 0.108 | 88.0% | 94.0% | 0.487 | 86.0% | 96.0% | 0.16 | |
T stage | T1–2 | 86.5% | 94.0% | 0.319 | 82.7% | 88.0% | 0.579 | 90.4% | 94.0% | 0.716 | 92.3% | 94.0% | 1 |
T3–4 | 92.1% | 90.0% | 1 | 86.8% | 82.5% | 0.756 | 94.7% | 85.0% | 0.264 | 89.5% | 92.5% | 0.708 | |
N stage | N0–1 | 97.4% | 100.0% | 1 | 94.7% | 92.1% | 1 | 97.4% | 94.7% | 1 | 97.4% | 94.7% | 1 |
N2–3 | 82.7% | 86.5% | 0.787 | 76.9% | 80.8% | 0.811 | 88.5% | 86.5% | 1 | 86.5% | 92.3% | 0.526 | |
Clinical stage | I-II | 100.0% | 100.0% | – | 95.5% | 95.5% | 1 | 95.5% | 100.0% | 1 | 100.0% | 95.5% | 1 |
III-IV | 85.3% | 89.7% | 0.605 | 80.9% | 82.4% | 1 | 91.2% | 86.8% | 0.585 | 88.2% | 92.6% | 0.561 | |